NCT02778906View on ClinicalTrials.gov

Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia

PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
ArthralgiaArthritis
Interventions
DRUG

Abatacept

Administration of Abatacept s.c. 125mg/weekly according to the Label for Rheumatoid arthritis

DRUG

Placebo

Administration of the comparator s.c. weekly in comparable to verum

Trial Locations (9)

60528

Centrum für innovative Diagnostik und Therapie (Ciri) Rheumatologie/Immunologie, Frankfurt

91054

University Clinic Erlangen, Erlangen

Unknown

Klinikum Bad Abbach, Bad Abbach

Charite Berlin, Berlin

Praxis für Rheumatologie und Innere Medizin, Berlin

Clinic Burghausen, Burghausen

Krankenhaus Porz Am Rhein, Cologne

Universitätsklinik Freiburg, Freiburg im Breisgau

Rheumazentrum Ruhrgebiet, Herne

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Erlangen-Nürnberg Medical School

OTHER

NCT02778906 - Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia | Biotech Hunter | Biotech Hunter